WO2014200325A3 - Consortium of the recombinant influenza a viruses flu-ns1-124- l7/l12-h5n1, flu-ns1-124-omp16-h5n1, flu-ns1-124-l7/l12-h1n1 and flu-ns1- 124-omp16-h1n1, family ortomyxoviridae, genus influenzavirus, expressing brucella immunodominant proteins destined to generate a vaccine against brucellosis - Google Patents

Consortium of the recombinant influenza a viruses flu-ns1-124- l7/l12-h5n1, flu-ns1-124-omp16-h5n1, flu-ns1-124-l7/l12-h1n1 and flu-ns1- 124-omp16-h1n1, family ortomyxoviridae, genus influenzavirus, expressing brucella immunodominant proteins destined to generate a vaccine against brucellosis Download PDF

Info

Publication number
WO2014200325A3
WO2014200325A3 PCT/KZ2014/000006 KZ2014000006W WO2014200325A3 WO 2014200325 A3 WO2014200325 A3 WO 2014200325A3 KZ 2014000006 W KZ2014000006 W KZ 2014000006W WO 2014200325 A3 WO2014200325 A3 WO 2014200325A3
Authority
WO
WIPO (PCT)
Prior art keywords
flu
omp16
nsl
vaccine
brucella
Prior art date
Application number
PCT/KZ2014/000006
Other languages
French (fr)
Other versions
WO2014200325A2 (en
Inventor
Abylay Rysbayuly SANSYZBAY
Kaisar Kazybayevich TABYNOV
Bolat Amanbayevich YESPEMBETOV
Kulyaisan Turlybayevna Sultankulova
Berik Mikhitovich KHAIRULLIN
Nurlan Tamambayevich Sandybayev
Andrei Yur'yevich YEGOROV
Original Assignee
The Republican Government Enterprise On The Basis Of Economic Control Rights "Research Institute For Biological Safety Problems" Of The Science Committee Of The Ministery Of Education And Science Of The Republic Of Kazakhstan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Republican Government Enterprise On The Basis Of Economic Control Rights "Research Institute For Biological Safety Problems" Of The Science Committee Of The Ministery Of Education And Science Of The Republic Of Kazakhstan filed Critical The Republican Government Enterprise On The Basis Of Economic Control Rights "Research Institute For Biological Safety Problems" Of The Science Committee Of The Ministery Of Education And Science Of The Republic Of Kazakhstan
Publication of WO2014200325A2 publication Critical patent/WO2014200325A2/en
Publication of WO2014200325A3 publication Critical patent/WO2014200325A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/098—Brucella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins

Abstract

This invention relates to the fields of biotechnology, veterinary science and public health, and describes a vector vaccine which can be used to prevent brucellosis. The essence of the invention is that reverse genetics methods have been used to construct novel, genetically-stable recombinant influenza viral vectors based on the influenza A viral vectors Flu-NSl-124-L7/L12- H5N1, Flu-NSl-124-Omp16-H5Nl, Flu-NSl-124-L7/L12-HlNl and Flu-NSl-124-Omp16- H1N1 (of the subtypes H5N1 and H1N1) that contain the genetic sequences of the Brucella proteins L7/L12 (ribosomal) or Omp16 (outer membrane) inserted into the viral NS1 gene, which express these Brucella proteins in vivo and are safe in cattle. Our studies showed that this vaccine candidate in cattle induced a strong antigen-specific T-cell immune response, and most importantly provided a high level of protectiveness comparable to the commercial B. abortus S19 vaccine and superior to the B. abortus S19 vaccine in combination with Montanide Gel01 adjuvant. Furthermore it is shown that the developed vaccines can effectively differentiate vaccinated animals from infected animals.
PCT/KZ2014/000006 2013-06-14 2014-05-23 Consortium of the recombinant influenza a viruses flu-ns1-124- l7/l12-h5n1, flu-ns1-124-omp16-h5n1, flu-ns1-124-l7/l12-h1n1 and flu-ns1- 124-omp16-h1n1, family ortomyxoviridae, genus influenzavirus, expressing brucella immunodominant proteins destined to generate a vaccine against brucellosis WO2014200325A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KZ20130790 2013-06-14
KZ2013/0790.1 2013-06-14

Publications (2)

Publication Number Publication Date
WO2014200325A2 WO2014200325A2 (en) 2014-12-18
WO2014200325A3 true WO2014200325A3 (en) 2015-04-02

Family

ID=51261191

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KZ2014/000006 WO2014200325A2 (en) 2013-06-14 2014-05-23 Consortium of the recombinant influenza a viruses flu-ns1-124- l7/l12-h5n1, flu-ns1-124-omp16-h5n1, flu-ns1-124-l7/l12-h1n1 and flu-ns1- 124-omp16-h1n1, family ortomyxoviridae, genus influenzavirus, expressing brucella immunodominant proteins destined to generate a vaccine against brucellosis

Country Status (1)

Country Link
WO (1) WO2014200325A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109116035A (en) * 2018-09-14 2019-01-01 重庆理工大学 A kind of Brucella antibody competition AlphaLISA detection kit and its detection method
CN111638329B (en) * 2020-06-09 2021-06-01 南方医科大学 ELISPOT detection kit for detecting brucellosis and application thereof
CN113637703B (en) * 2021-08-06 2023-08-25 河北科技师范学院 Construction method and application of Brucella L7/L12 and GroES eukaryotic expression vector

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102703505A (en) * 2012-05-18 2012-10-03 中国农业科学院兰州兽医研究所 Co-expressed brucella recombinant adenovirus as well as preparation method and use thererof
EP2535405A1 (en) * 2009-11-18 2012-12-19 "Repulican Governmental Enterprise on the right of Economic Management "Research Institute for Biological Safety Problems" of The Science A recombinant a/astanarg/6:2/2009 m-12-09/d flu virus strain produced by a reverse genetics method from a highly pathogenic donor strain a/chicken/astana/6/05 (h5n1) and a highly reproductive donor strain a/puerto rico/8/34 (h1n1) from the orthomyxoviridae family of the genus influenza virus type a which is deposited in the microorganism collection of the science committee at the ministry of education and science of the republic of kazakhstan state enterprise subsidiary of the scientific research institute for biological safety problems at the republican state enterprise of the national centre for biotechnology of the republic of kazakhstan and can be used in biotechnology for the production of diagnostic and vaccine preparations against a/h5n1 flu

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2535405A1 (en) * 2009-11-18 2012-12-19 "Repulican Governmental Enterprise on the right of Economic Management "Research Institute for Biological Safety Problems" of The Science A recombinant a/astanarg/6:2/2009 m-12-09/d flu virus strain produced by a reverse genetics method from a highly pathogenic donor strain a/chicken/astana/6/05 (h5n1) and a highly reproductive donor strain a/puerto rico/8/34 (h1n1) from the orthomyxoviridae family of the genus influenza virus type a which is deposited in the microorganism collection of the science committee at the ministry of education and science of the republic of kazakhstan state enterprise subsidiary of the scientific research institute for biological safety problems at the republican state enterprise of the national centre for biotechnology of the republic of kazakhstan and can be used in biotechnology for the production of diagnostic and vaccine preparations against a/h5n1 flu
CN102703505A (en) * 2012-05-18 2012-10-03 中国农业科学院兰州兽医研究所 Co-expressed brucella recombinant adenovirus as well as preparation method and use thererof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CABRERA A ET AL: "Vaccination with recombinant Semliki Forest virus particles expressing translation initiation factor 3 of Brucella abortus induces protective immunity in BALB/c mice", IMMUNOBIOLOGY, URBAN UND FISCHER VERLAG, DE, vol. 214, no. 6, 1 June 2009 (2009-06-01), pages 467 - 474, XP026097400, ISSN: 0171-2985, [retrieved on 20090117], DOI: 10.1016/J.IMBIO.2008.11.016 *
D. LUO ET AL: "Protective Immunity Elicited by a Divalent DNA Vaccine Encoding Both the L7/L12 and Omp16 Genes of Brucella abortus in BALB/c Mice", INFECTION AND IMMUNITY, vol. 74, no. 5, 1 May 2006 (2006-05-01), pages 2734 - 2741, XP055072846, ISSN: 0019-9567, DOI: 10.1128/IAI.74.5.2734-2741.2006 *
DATABASE WPI Week 201309, Derwent World Patents Index; AN 2013-A78536, XP002736123 *
KAISSAR TABYNOV ET AL: "Influenza viral vectors expressing the Brucella OMP16 or L7/L12 proteins as vaccines against B. abortus infection", VIROLOGY JOURNAL, BIOMED CENTRAL, LONDON, GB, vol. 11, no. 1, 10 April 2014 (2014-04-10), pages 69, XP021182141, ISSN: 1743-422X, DOI: 10.1186/1743-422X-11-69 *
OLIVEIRA SÉRGIO COSTA ET AL: "Confronting the barriers to develop novel vaccines against brucellosis.", EXPERT REVIEW OF VACCINES SEP 2011, vol. 10, no. 9, September 2011 (2011-09-01), pages 1291 - 1305, XP002736124, ISSN: 1744-8395 *
SEREINIG S ET AL: "Influenza virus NS vectors expressing the mycobacterium tuberculosis ESAT-6 protein induce CD4+ Th1 immune response and protect animals against tuberculosis challenge", CLINICAL AND VACCINE IMMUNOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, vol. 13, no. 8, 1 August 2006 (2006-08-01), pages 898 - 904, XP002604135, ISSN: 1556-6811, DOI: 10.1128/CVI.00056-06 *
TABYNOV KAISSAR ET AL: "Novel influenza virus vectors expressingBrucellaL7/L12 or Omp16 proteins in cattle induced a strong T-cell immune response, as well as high protectiveness againstB. abortusinfection", VACCINE, vol. 32, no. 18, 2 March 2014 (2014-03-02), pages 2034 - 2041, XP028838503, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2014.02.058 *

Also Published As

Publication number Publication date
WO2014200325A2 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
MX352974B (en) Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof.
PH12019501130A1 (en) Viral delivery of neoantigens
CO2017007105A2 (en) New tilapia viruses
EA201201025A1 (en) NUCLEIC ACID MOLECULES OF INFLUENZA AND VACCINES PRODUCED FROM THEM
DK2643345T5 (en) IMMUNOGENIC PEPTIDES FOR USE FOR PREVENTION AND / OR TREATMENT OF INFECTIOUS DISEASES, AUTOIMMUNE DISEASES, immune responses to ALLOFAKTORER, ALLERGY DISEASES, TUMORS, transplant rejection and immune responses to viral vectors USED FOR GENE THERAPY OR gene vaccination
MX343830B (en) Nucleic acid molecule encoding hepatitis b virus core protein and vaccine comprising the same.
PH12014502534A1 (en) Effective vaccination against porcine reproductive and respiratory syndrome (prrs) virus prior to weaning
MX2020011804A (en) Hepatitis b virus (hbv) vaccines and uses thereof.
MX351643B (en) Recombinant ndv antigen and uses thereof.
WO2014200325A3 (en) Consortium of the recombinant influenza a viruses flu-ns1-124- l7/l12-h5n1, flu-ns1-124-omp16-h5n1, flu-ns1-124-l7/l12-h1n1 and flu-ns1- 124-omp16-h1n1, family ortomyxoviridae, genus influenzavirus, expressing brucella immunodominant proteins destined to generate a vaccine against brucellosis
PH12017501100A1 (en) Recombinant swinepox virus and vaccines
EA201691120A1 (en) VECTOR COMPOSITIONS AND METHODS OF INDUCTION OF STRENGTHENED IMMUNE RESPONSE USING POXVIRUS VECTORS
NZ596223A (en) Combined measles-malaria vaccine
MX338052B (en) Parapoxvirus vectors containing rabies virus antigen.
PH12020500526A1 (en) Paramyxoviridae expression system
PH12014502085B1 (en) Modified marek`s disease virus, and vaccines made therefrom
WO2013011179A3 (en) Recombinant vectors based on the modified vaccinia ankara (mva) virus, with deletion in the c6l gene, as vaccines against hiv/aids and other diseases
MX2018013358A (en) Vaccines for human papillomavirus and methods for their use.
UA95831U (en) Vaccine strain "n 120" (clone 311) genus coronavirus kind infectious bronchitis virus serotype massachusetts for the vaccine production

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14745240

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14745240

Country of ref document: EP

Kind code of ref document: A2